On November 20, 2025 CuraCell reported the publication of its latest research article, "Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer," in the peer-reviewed journal Frontiers in Oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study provides novel insights into how Tumor-Infiltrating Lymphocyte (TIL) therapy, when combined with PD-1 blockade, can drive durable immune responses and lasting clinical remission—even in prostate cancer, a tumor type historically resistant to immunotherapy.
In this longitudinal case study, a patient with treatment-refractory metastatic prostate cancer achieved complete and sustained tumor remission lasting over five years following multiple TIL infusions combined with anti–PD-1 therapy. Using high-throughput T-cell receptor (TCR) sequencing over a five-year period, researchers tracked the persistence and evolution of both infused and endogenous T-cell clonotypes, revealing long-term clonal persistence, robust immune reactivation, and the emergence of new tumor-reactive T-cell clones correlating with tumor regression.
"This work demonstrates the remarkable potential of combining TIL therapy with PD-1 blockade to overcome immune resistance in solid tumors," said Lucas Arruda, CSO of CuraCell. "By achieving durable immune control in prostate cancer, we are expanding the boundaries of what TIL-based immunotherapy can accomplish."
The full article, "Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer," is published in Frontiers in Oncology and can be accessed here.
"These findings reinforce the importance of longitudinal immunogenomic monitoring in personalized cell therapy," added Arruda. "They strengthen the scientific foundation for exploring combined adoptive T-cell transfer and checkpoint blockade strategies to extend clinical benefit in solid ‘cold’ tumors."
(Press release, CuraCell, NOV 20, 2025, View Source [SID1234661189])